Feb 20, 2024
|
Vertex to Participate in Upcoming Investor Conferences
|
|
Feb 13, 2024
|
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
|
|
Feb 05, 2024
|
Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
|
|
Feb 05, 2024
|
Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis
|
|
Jan 30, 2024
|
Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
|
|
Jan 17, 2024
|
Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
|
|
Jan 16, 2024
|
Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
|
|
Jan 09, 2024
|
Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arabia
|
|
Jan 07, 2024
|
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
|
|
Dec 18, 2023
|
Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
|
|
Dec 15, 2023
|
Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
|
|
Dec 13, 2023
|
Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
|
|
Dec 11, 2023
|
Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition
|
|
Dec 08, 2023
|
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
|
|
Dec 05, 2023
|
Vertex Appoints Nancy Thornberry to its Board of Directors
|
|
Nov 24, 2023
|
Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO® in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations
|
|
Nov 23, 2023
|
European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5
|
|
Nov 16, 2023
|
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
|
|
Nov 06, 2023
|
Vertex Reports Third Quarter 2023 Financial Results
|
|
Nov 02, 2023
|
Vertex to Present New Data on Exagamglogene Autotemcel (exa-cel) at the American Society of Hematology (ASH) Annual Meeting and Exposition
|
|